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Abstract Drug vehicles are chemical carriers that provide
beneficial aid to the drugs they bear. Taking advantage of their
favourable properties can potentially allow the safer use of
drugs that are considered highly toxic. A means for vehicle
selection without experimental trial would therefore be of
benefit in saving time and money for the industry. Although
machine learning is increasingly used in predictive toxicol-
ogy, to our knowledge there is no reported work in using
machine learning techniques to model drug-vehicle relation-
ships for vehicle selection to minimise toxicity. In this paper
we demonstrate the use of data mining and machine learn-
ing techniques to process, extract and build models based on
classifiers (decision trees and random forests) that allow us
to predict which vehicle would be most suited to reduce a
drug’s toxicity. Using data acquired from the National Insti-
tute of Health’s (NIH) Developmental Therapeutics Program
(DTP)we propose amethodology using an area under a curve
(AUC) approach that allows us to distinguish which vehicle
provides the best toxicity profile for a drug and build classi-
fication models based on this knowledge. Our results show
that we can achieve prediction accuracies of 80 % using ran-
dom forest models whilst the decision tree models produce
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accuracies in the 70 % region. We consider our methodology
widely applicablewithin the scientific domain andbeyond for
comprehensively building classification models for the com-
parison of functional relationships between two variables.
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1 Introduction
Pharmaceutical drug toxicity is a major concern facing the
drug discovery industry today, resulting in not only high drug
attrition rates but increased developmental costs (Basavaraj
and Betageri 2014), which may not be recovered if the drug
does not make it to market. Of particular concern are the
anticancer compounds for which it is estimated that 95 % of
the attrition rates are related to toxicity concerns (Hutchin-
son and Kirk 2011), which is unsurprising given the nature
of their modes of action as cytotoxics. Safe, effective use
of anticancer drugs is often limited by their dose-dependent
toxicities typically associating such drugswith a narrow ther-
apeutic index (NTI) (Liang et al. 2013). In a study involving
hospitalised patients using NTI drugs compared to non NTI
drugs, it was shown that more drug-related problems (DRPs)
were associated with NTI drugs, of which adverse drug reac-
tions was one of the eight categories considered to be a DRP
(Blix et al. 2010).
Toxicity prediction without experimental effort is a major
area of study in the field of toxicology. The ability to predict
the nature of the toxicity of a previously untested chemical
structure is highly desirable to a drugdiscovery teamdeciding
which chemical structures they should continue developing.
The ability tomake informeddecisions can not only save time
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and money but also bring new drugs to market sooner, ben-
efiting the patient population as a whole. Using historical in
vivo and in vitro experimental data for in silico predictions is
a challengingproblem.Making suchpredictions involves soft
computing approaches that use quantitative structure activ-
ity relationships (QSAR’s) to relate the activity (toxicity) of
a chemical to its structure (Eldred and Jurs 1999; Eldred
et al. 1999). Many useful computational models have been
developed with varying success. Models ranging from stud-
ies on aquatic toxicity that utilise multiple linear regression
and neural networks (Eldred et al. 1999) through to predic-
tive hepatotoxicity (Cruz-Monteagudo et al. 2008; Low et al.
2011 andmutagenicity (Bakhtyari et al. 2013; Xu et al. 2012;
Modi et al. 2012) that use k-nearest neighbour, support vec-
tor machines and random forests are frequently reported in
literature.
In this study we report on a methodology developed to
buildQSAR classificationmodels based on drug-vehicle tox-
icity relationships. As more data becomes publicly available
new methodologies are required to extract the relevant infor-
mation that enables successful predictive models to be built.
Using data frequently reported in toxicity studies we utilise
existing data and develop a methodology that is applicable
across the wider domain which could be adapted for other
similar predictive problems. Specifically we employ an area
under the curve (AUC) approach to discriminate between the
toxicity classes of different drug vehicles.Abinary classifica-
tion model is built using C4.5 decision tree (DT) and random
forest (RF) algorithms asmachine learningmethodswith pre-
dictive accuracies in the 70 and 80% range respectively. That
is, our models are able to predict which vehicle will provide
the better toxicity relief to a particular chemical drug.
The remainder of this paper is arranged as follows: Sect. 2
provides some background information that briefly describes
the purpose of drug vehicles and how they are able to reduce
a drug’s toxicity. Section 3 describes our proposed approach
to building classifiers based on our AUC methodology. Sec-
tion 4 discusses the dataset we acquired, its content and the
challenges faced when using it. Section 5 provides the exper-
imental details of our work. Section 6 reports the results
generated from our predictive models and provides the dis-
cussion to this work. Section 7 ends this study with our
conclusion.
2 Background
Toovercomeproblems relating to the toxicity of a drug signif-
icant efforts are made. Some involve the use of drug vehicle
formulations that can considerably attenuate this toxicity,
allowing the safer use of a potent yet highly toxic compound.
Drug vehicles behave as “carriers” that aid the administration
and distribution of a drug through an organism and with con-
sidered selection canmaximise the efficacy andminimise the
side effects. For instance, studies have shown that vehicles
can be selected to improve the solubility and/or permeabil-
ity of a drug or to target the drug to a specific disease site
(Loftsson 1998; Porter et al. 2007; Shin et al. 2009; Hans and
Lowman 2002; Liu et al. 2011; Lee et al. 2003).Vehicles have
also been designed and formulated to mitigate unwanted tox-
icities associated with drugs that are considered highly toxic
(Huo et al. 2010; Uchino et al. 2005; Kelava et al. 2010).
Vehicles offer toxicity relief in several ways. A vehicle that
improves the solubility or permeability of a drug removes
this rate limiting step (Savjani et al. 2012) in the drug’s
absorption profile and so may provide some form of local
toxicity relief, that is, toxicity at a local site, typically the
site of administration. For instance, studies on the antifun-
gal drug amphotericin B have shown that its precipitation
upon infusion is related to its acute toxicity. Solubilisation
of amphotericin B using polymeric micelles, has resulted in
a reduced haemolytic activity of the drug (Yu et al. 1998).
Similarly the use of cyclodextrins to enhance the gastroin-
testinal absorption of tacrolimus was shown to reduce renal
and neural toxicity in rats (Arima et al. 2001).
A drug that is toxic to a particular organ may be formu-
lated to avoid accumulation within that organ, or targeted to a
specific disease site such as a tumour thus avoiding accumu-
lation within other organs. This type of vehicle formulation
involves the modulation of a drug’s plasma concentration,
ensuring it remains below the toxicity threshold but above a
level needed for efficacy. Vehicles that alter a drug’s pharma-
cokinetic properties can reduce toxicity by limiting the Cmax
(peak plasma concentration) (Kim et al. 2001; Italia et al.
2007). Two drug vehicles may exhibit the same area under
the plasma-drug concentration curve for the same drug, but
the vehicle associated with a higher Cmax value may pro-
duce a toxic outcome compared to a vehicle which produces
a flatter and more prolonged plasma drug concentration pro-
file (Fig. 1).
For a drug to produce observable toxicity effects it must
exceed a toxicity threshold. The use of vehicle formulations
can significantly alter the pharmacokinetic profile of a drug to
prevent it exceeding this toxicity threshold. Figure 1 concep-
tualises this using the hypothetical drug X. While vehicle A
produces a spike in the plasma-drug concentration curve and
exceeds the toxicity threshold, vehicle B produces a flatter,
prolonged plasma-drug concentration curve which remains
below the toxicity threshold. Vehicle B therefore does not
result in any measurable toxicity outcome but can still pro-
vide therapeutic benefit.
An alternative method for modulating a drug’s toxicity
is with the aid of co-administrative agents. Such agents can
be other drugs, protein extracts, vitamins or oils. They work
not by altering a drug’s pharmacokinetic profile but instead
by countering or moderating the drug’s toxic manifestation
123
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Fig. 1 Area under the plasma-drug concentration curve for drug X for-
mulated using vehicles A and B. Vehicle A results in a concentration
spike at approximately 8 h which exceeds the toxicity threshold, whilst
the same drug formulated using vehicle B produces a flatter more pro-
longed course of absorption that does not exceed the toxicity threshold
but still provides an equivalent if not better total exposure compared to
vehicle A
and providing some form of toxicity relief. For example this
relief may come in the form of antioxidant benefits related to
these co-administrative agents. Vitamins C and E are known
to provide nephroprotective effects to cisplatin induced kid-
ney injury in mice (Ajith et al. 2007; Maliakel et al. 2008).
Other co-administrative agents may behave as deactivators
of toxicity pathways that are initiated upon drug administra-
tion. Acetaminophen is a globally used analgesic that results
in hepatic injury at high doses. It is not the parent drug but
rather its reactivemetaboliteN-acetyl-p-benzoquinone imine
(NAPQI) that results in hepatic injury (James et al. 2003;
Hodgman and Garrard 2012). Whilst at low acetaminophen
doses, NAPQI is deactivated via conjugation to endoge-
nous glutathione, at high doses glutathione becomes depleted
leaving the reactive metabolite NAPQI to bind covalently
to hepatic proteins resulting in hepatotoxicity. In humans
the most commonly associated cytochrome P450 enzymes
that result in NAPQI production are CYP2E1, CYP1A2 and
CYP3A4, of which CYP2E1 accounts for the greatest trans-
formation (Lee et al. 1996; Patten et al. 1993). Lee et al.
investigated the co-administrative use of chlormethiazol, an
inhibitor of CYP2E1, with high doses of acetaminophen.
They demonstrated that chlormethiazol was able to prevent
liver injury in mice resulting in the survival of mice adminis-
tered a high dose (500 mg/kg) of acetaminophen. A greater
than 50 % death rate was observed in mice that were not
co-administered chlormethiazol (Lee et al. 1999).
2.1 Measuring toxicity
Experimental toxicity ismeasured in several ways depending
on the chosen outcome of the study. For acute toxicity the
lethal dose 50 (LD50) or maximum tolerated dose (MTD)
is used (Kim et al. 2001; Kaminskas et al. 2012; Larabi
et al. 2004). Whilst for specific organ toxicity, irregulari-
ties in organ function such as the glomerular filtration rate
(GFR) for the kidneys (Mora et al. 2003) or the QT inter-
val for the heart can be measured (Pereverzeva et al. 2007).
Organ weights or total animal body weights compared to a
control can also be useful indications of toxicity (Pereverzeva
et al. 2007; Injac et al. 2008).
Organ specific biomarkers are frequently reported when
studying toxicity relating to a specific organ. Using biomark-
ers is advantageous because it allows toxicity measurements
to be assessed at lower levels of toxicity and over a speci-
fied time period in a non-invasive manner. Biomarkers are
typically measured through blood samples using bioassays
to assess the biomarkers of interest. Liver toxicity is one of
the most common toxicity endpoints measured since most
xenobiotics are metabolised via the liver. Aspartate transam-
inase (AST) and alanine transaminase (ALT) are two such
biomarkers associated with liver toxicity (Garg et al. 2007;
Lee et al. 2012; Das et al. 2011).
2.2 Study objective
In this study we repurpose (Loshin 2010) a dataset obtained
from the National Cancer Institute’s Developmental Ther-
apeutics Program (DTP) (DTP 2000). This is a dataset
compiled from their in vivo screening program against vari-
ous inoculated cancer cell lines to assess the effectiveness of
different compounds against a developing tumour. It contains
records compiled from the 1950s through to the late 1980s.
Each compound was tested by one or more laboratory
(screener) at various doses against different cancerous cell
lines to assess their ability as tumour reducing agents. Exper-
iments were conducted in various strains of mice, rats and
hamsters using different dosing schedules and administration
routes. Test compounds were administered using a range of
vehicles. As ameasure of toxicity, the survival rate on a spec-
ified day was recorded.
Whilst the primary objective of the DTP was to discover
anticancer compounds, we have repurposed and mined this
dataset to establish drug-vehicle toxicity relationships. From
this we propose a methodology to extract drug-vehicle toxic-
ity relationships andpresent ameans of pairwise comparisons
to be made between different vehicles offering differing lev-
els of toxicity protection. We build classifiers using C4.5
decision trees (DT) and random forests (RF) to demonstrate
that our methodology can be used to build predictive models
with success rates in the range of 70–80 % accuracy.
Whilst there is published work in the field of predictive
toxicology, to our knowledge we are the first to build com-
putational models based on soft computing techniques for
vehicle-toxicity predictions.
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3 Methodology
We propose a methodology of extracting the relevant infor-
mation from our dataset and processing this using an area
under the curve approach to assign classification of vehicles.
This approach can be used for a multitude of problems that
compare the functional relationship of two variables for dif-
ferent objects (vehicles in our case). Section 2.1 discusses
some ways in which toxicity is commonly measured. In our
study, toxicity was measured as animal survival per dose
administered. Given this we are able to extract dose-survival
relationships for drugs that are administered using different
vehicles.
For any vehicle Vk for any given drug we consider it rep-
resented by two arrays Dk and Sk , which are of equal size,
n, (n ≥ 2) where Dk = [dk1 . . . dkn
]
and Sk = [sk1 . . . skn
]
,
Dk is the dose amount array and Sk is the survival array:
V k = {Dk, Sk}. Elements of array Dk are ordered ascend-
ingly: dk1 < d
k
n where n > 1. In this case the value s
k
1
represents the survival for the smallest dose amount of drug
using vehicle Vk , and the value skn represents the survival
value for the largest dose amount of drug using vehicle Vk .
For two different vehicles (V1 and V2) used to test the
samedrug aplot ofS1 againstD1 wouldproduce adoseversus
survival curve for vehicle V1 and likewise a plot of S2 versus
D2 would produce a curve for vehicle V2. Calculating their
respective area under the curves can then be used to compare
the toxicity difference afforded by the vehicles. Whist the
elements in the arrays for V1 may not be equivalent in length
or value to the elements in the arrays for V2 it is important
to ensure that the maximum number of data points spanning
the largest possible area under the dose versus survival curve
is used to compare the toxicity difference between the two
vehicles.
For simplicity let us consider vehicles V1 and V2 and the
arrays they represent. To maximise data comparison these
arrays were subjected to further extrapolation and interpola-
tion before AUCs were calculated.
3.1 Extrapolation
Extrapolation was considered beyond the maximum and/or
below the minimum dose for each array. For vehicles V1
and V2, their respective dose amount and survival values
were compared. Extrapolation was considered for V1 if its
minimum dose amount was greater than the minimum dose
amount of V2 and survival at the minimum dose was 100 %.
Likewise if the maximum dose amount of V1 was less than
then maximum dose amount of V2 and survival at the maxi-
mum dose was 0 % then extrapolation was also a possibility.
Consider the set of arrays for V1 and V2 below:
Dose amount (mg/kg) for V1 (D1):
[15, 20, 30, 40, 50, 60]
% survival for V1 (S1):
[100, 100, 100, 70, 30, 0]
Dose amount (mg/kg) for V2 (D2):
[10, 20, 30, 40, 50, 60, 70]
% survival for V2 (S2):
[100, 100, 100, 80, 50, 30, 10]
Given that the minimum dose amount for V1 (15 mg/kg)
is greater than the minimum dose for V2 (10 mg/kg), and
the survival for V1 at the minimum dose is 100 % then it is
reasonable to assume that the survival of V1 at a mock dose
of 10 mg/kg would also be 100 %. At the opposite end of
the array a similar assumption can be made. Given that the
maximum dose amount for V1 (60 mg/kg) is less than the
maximum dose for V2 (70 mg/kg), and the survival for V1 at
the maximum dose is 0% then it is reasonable to assume that
the survival of V1 at a mock dose of 70 mg/kg would also be
0 %. The extrapolated arrays for V1 would then look like:
(Extrapolated values underlined)
Extrapolated Dose amount (mg/kg) for V1 (D1):
[10, 15, 20, 30, 40, 50, 60, 70]
Extrapolated % survival for V1 (S1):
[100, 100, 100, 100, 70, 30, 0, 0]
Extrapolation could occur at both ends of the array, one end
of the array, or neither end depending on the dose amounts
and only if the survival values are 100 or 0% for theminimum
and maximum doses respectively.
The pre- and post- extrapolated curves for V1 and V2 are
shown in Figs. 2 and 3 below.
Using this extrapolation method allows more data points
to be used when calculating the AUCs for vehicles V1 and
V2.
3.2 Interpolation
Interpolation was considered if extrapolation was not achiev-
able. Namelywhen theminimum andmaximumdoses of one
vehicle represented survival values of <100 or >0% respec-
tively. With such instances, the assumptions made during
extrapolation could not be used. Therefore to maximise the
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Fig. 2 Pre-extrapolated curve for V1 and V2
Fig. 3 Post-extrapolated curve for V1 and V2. The extrapolated data
points for V1 are shown in green (colour figure online)
number of data points we can use to calculate their respective
AUCs, interpolation of data was employed.
Consider the set of arrays for V3 and V4 below:
Dose amount (mg/kg) for V3 (D3):
[5, 20, 30, 40, 50, 80]
% survival for V3 (S3):
[90, 80, 70, 60, 30, 10]
Dose amount (mg/kg) for V4 (D4):
[10, 20, 30, 40, 50, 60, 70]
% survival for V4 (S4):
[100, 100, 80, 70, 40, 30, 25]
The two array sets above for vehicles V3 and V4 are com-
parable over the common dose range of 20–50 mg. Since
the criteria for extrapolation are not satisfied (see Sect. 3.1),
Fig. 4 Pre-interpolated curve for V3 and V4
linear interpolation between data points can be used. Given
that the minimum dose for V4 is 10 mg, this value can be
interpolated from the data points of V3 between the doses of
5 mg and 20 mg.
To interpolate a % survival value for V3 (S3n) at a mock
dose of 10 mg/kg (D3n) we have two dose amounts given by
D31 and D
3
2 and their corresponding % survival values of S
3
1
and S32 . The value for S
3
n along the straight line is given by:
S3n = S31 + (S32 − S31)
(D3n − D31)
(D32 − D31)
(1)
where D31 = 5 mg/kg,D32 = 20 mg/kg, S31 = 90 %, S32 =
80 % and D3n = 10 mg/kg, then S3n = 86.6%
Similarly if extrapolation at the high dose end of D3
was not possible then interpolation between two points that
contained a common dose value contained within D4 was
calculated. In the example above, a value of 70 mg/kg would
be interpolated into the array V3 with its corresponding %
survival value added to the array S3.
The interpolated arrays for V3 would then look like:
(Interpolated values underlined)
Interpolated Dose amount (mg/kg) for V3 (D3):
[5, 10, 20, 30, 40, 50, 70, 80]
Interpolated % survival for V3 (S3):
[90, 86.6, 80, 70, 60, 30, 16.6, 10]
The pre- and post- interpolated curves for V3 and V4 are
shown in Figs. 4 and 5 below.
Both extrapolation and interpolation increase the max-
imum common dosage range over which two different
vehicles can be compared, maximising the number of data
points from the dataset that can be used.
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Fig. 5 Post-interpolated curve for V3 and V4. The interpolated data
points for V3 are shown in green (colour figure online)
3.3 AUC calculation
After extrapolation/interpolation, the area under the dose
versus % survival curve (AUC) for the two vehicles was cal-
culated over the maximum common dosage range possible.
Given the dosage range
{
Dn1 . . . D
n
x
}
that corresponds to a
% survival array of
{
Sn1 . . . S
n
x
}
, the AUC is calculated as
follows:
AUC =
X−1∑
x=1
(Dnx+1 − Dnx )(
Snx + Snx+1
2
) (2)
AUCs for two vehicles used with the same drug can then be
compared to seewhich provides the better toxicity protection.
Over a common dose range the greater the difference in AUC
between the vehicles the greater reassurance we can have
that the difference is real. It is important to set a threshold for
which it will be considered that the differences are significant
or not. For example a difference in theAUCs of say 10%may
be taken as significant and for any comparisons that result
in an AUC difference of <10 % are considered equivalent.
The threshold is set with careful consideration of the data
used, how reliable a researcher feels the data are and how
much signal-to-noise the data may contain. For a dataset that
potentially contains high noise levels, some experimentation
may be necessary before a threshold can be set. For our study
we set this AUC difference threshold to 30, 40 and 60 % (see
Sect. 5).
4 Dataset
For this study we used the in vivo screening dataset obtained
from theNational Institutes of Health’s Developmental Ther-
apeutics Program (DTP) (DTP 2000). This dataset contained
2,724,199 records, detailing experimental in vivo screening
results of 227,093 potential cytotoxic drug candidates. Their
Fig. 6 Distribution frequency of the vehicles per unique drug com-
pound within our dataset. A total of 39 vehicles were present within
our dataset of which some vehicles have been used more frequently
than others. The five most frequently used vehicles are shown with the
remaining grouped as ‘Other’
aim was to assess the ability of the drug candidate to reduce
the size of a tumour cell line inoculated onto a host. Each drug
was administered using a carrier in the form of a drug vehi-
cle. There are 39 different vehicles used within the dataset
for which some vehicles had been used more frequently than
others (Fig. 6).
Whilst we do not consider our dataset to be “big data” as
defined by several proposed definitions of big data, it does
meet some of the criteria that are generally accepted (Laney
2001; Berman 2013; Hashem et al. 2015). Big data is not
simply a large volume of data or a large structured database
containing lots of records. There are several proposed defini-
tions that currently exist to define big data of which the three
V’s is the most prominent.
The three V’s define big data as:
Volume—this refers to the amount of the data being large
and often derived from various sources.
The size of our dataset is indeed large, approximately 2.7
million records, and these data have been compiled from
different sources given that there were several different labo-
ratories (screeners) that produced these data. This gives rise
to the complexity of how reliable the data from multiple
sources can be, each of which will carry a different error rate
associated with the data they generate making comparisons
across sources challenging.
Variety—Variety means that the data come in different
forms or collected via different means.
This is true to some extent with our dataset given that
different laboratories (screeners) were involved in generating
and reporting the data. However, the form inwhich these data
have been compiled is the same across all screeners.
Velocity—Velocity is the speed at which the data are
generated which means the dataset is dynamic due to the
absorption of complementary data.
123
Using random forest and decision tree models...
Our large dataset is not changing dynamically or increas-
ing in size. Most of these data were generated from the early
1950s up until the late 1980s. It covers an era where comput-
ers were not widely used across industries as they are used
today. A large proportion of the dataset we are working with
was only available electronically due to a substantial effort
made to translate all the data from a hard copy format into
a digital one (DTP 2000). Our dataset does however carry
the possibility of having complimentary data added to it. If
similar data become available from alternative sources then
there is no reason why some form of data integration cannot
occur between the datasets. For our work no additional data
were added to the original dataset we acquired.
Presented with some big data challenges our dataset con-
taining approximately 2.7 million records with drug-vehicle
relationships was investigated. Working with big data does
not always lead to novel discoveries, but presents challenges
of its own as discussed above. The main purpose of this
studywas to propose and develop amethodologywhat would
enable the extraction of drug-vehicle comparisons in order
to build classifiers.
5 Experimental work
5.1 Initial data curation
To make toxicity comparisons, we mined our dataset to pro-
duce dose amounts against survival plots for compounds
tested using the same experimental conditions across two or
more different vehicles. These vehicles were then compared
pairwise. Doing this enables comparisons between the differ-
ent toxicity protection levels for two different vehicles to be
compared. All our data processing was accomplished using
a Knime (version 2.10.1) (Knime 2000) workflow. Informa-
tion held within the dataset was interpreted using a document
referred to as ‘Instruction_14,’ available for download from
the DTP website (DTP 2000). Whilst it was important to
retain and keep important experimental conditions constant
when making comparisons, it was also necessary to aggre-
gate on other fields not considered to influence experimental
outcome. Such fields included but were not limited to the
date of the experiment or the laboratory (screener) where
the experiment was conducted. Aggregating on such fields
allowed a greater number of drug-vehicle comparisons to be
made.
Several columns carried information about the inoculated
cell line used in these experiments. We were not concerned
with such information and so any columns carrying tumour
cell line information were removed from the data table.
Whilst it is possible that a developing tumour could affect
the survival outcome of an animal, we felt that we could
aggregate on such columns since survival outcome (toxday)
Table 1 List of columns retained after initial data curation
Original column heading Description of column
NSC Identification number of
compound tested
(NSC-National Service
Center)
HOST_GROUP_CD Type of animal
HOST_CD Species/strain of animal used
ADMIN_ROUTE Route of administration of drug
being tested
INTERVAL Time between treatment
(dosing) in terms of interval
unit
INTERVAL_UNIT Minutes (M), hours (H) or days
(D)
VEHICLE_CD Vehicle used
NUMBER_INJECTIONS Total number of injections
administered
FIRST_INJECTION_DAY Day of first administration
injection relative to day zero
(inoculation)
REPETITION Repetition of injection cycle
RESTART_DAYS Days on which repetition
occurs
DOSE_AMOUNT Dose in mg/kg unless otherwise
stated
TOXDAY Day toxicity is measured on
SURVIVOR_NUMBER_START Animal count at start of
experiment
SURVIVOR_NUMBER_TOXDAY Animal count on toxday
The columns listedwere considered influential to experimental outcome
i.e. animal survival
was recorded on day 0 (zero) or day 5 after the first dose
was administered and as such the toxicity outcome would be
largely influenced by the drug administered rather than the
developing tumour.
The columns that were retained were considered relevant
enough to affect the toxicity outcome of the experiments.
These key columns are listed in the table below (Table 1)
with their original heading name and a brief description of
their value.
Upon removal of all unnecessary columns, individual
records within the data table were further curated. Any
records considered erroneous were removed from the data
table. For example if the animal count at the end of an
experiment (SURVIVOR_NUMBER_TOXDAY) exceeded
the survivor count at the start of an experiment (SUR-
VIVOR_NUMBER_START), these records were removed.
Records that contained missing values in important fields
were also entirely removed from the data table. Examples of
this include if the vehicle (VEHICLE_CD), or dose amount
(DOSE_AMOUNT) fields were empty.
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Upon this initial data curation our data table was reduced
to 2,710,014 records. Typically these in vivo experiments
used 6 or 10 animals to beginwith (SURVIVOR_NUMBER_
START). To compare experiments that used 6 animals
with those that used 10 we simply calculated the per-
centage survival rate (% survival), which was the SUR-
VIVAL_NUMBER_END/SURVIVAL_NUMBER_START
* 100. Since our dataset contained replicate experiments that
resulted in slight differences in experimental outcome, it was
necessary to then take a mean of the % survival values across
replicate experiments (% mean survival).
To generate dose versus ‘% mean survival’ plots we
grouped data that carried the same experimental con-
ditions, that is: NSC, HOST_GROUP_CD, HOST_CD,
ADMIN_ROUTE, INTERVAL_UNIT, INTERVAL, NUM-
BER_INJECTIONS, FIRST_INJECTION_DAY, REPETI-
TION, RESTART_DAYS and TOXDAY. Grouping on these
fields allowed an array of lists to be constructed of the
DOSE_AMOUNT, % mean survival and VEHICLE_CD
fields. These lists were held as arrays that were used to plot
the dose amount versus %mean survival curves. An example
of the array lists generated from our dataset is shown below:
DOSE_AMOUNT (mg/kg):
[300, 1000, 3300, 10000, 300, 1000, 3300, 10000]
% mean survival:
[100, 100, 33, 0, 100, 100, 100, 67]
VEHICLE_CD:
[Saline,Saline,Saline,Saline,CMC,CMC,CMC,CMC]
CMC = Carboxymethylcellulose
Once the array lists were extracted, they were used for the
pairwise comparison of two vehicles. In the example above,
the array lists are split into their corresponding vehicle arrays.
DOSE_AMOUNT (mg/kg) (saline):
[300, 1000, 3300, 10000]
% mean survival (saline):
[100, 100, 33, 0]
DOSE_AMOUNT (mg/kg) (CMC):
[300, 1000, 3300, 10000]
% mean survival (CMC):
[100, 100, 100, 67]
Fig. 7 The two vehicles (Saline and CMC) that show quite distinct
AUC profiles when formulated with drug compoundNSC 63479. At the
two lower doses (300 and 1000mg/kg) there is no observable difference
between the vehicles, with both showing a survival rate of 100%.As the
doses increase to 3300 and 10,000 mg/kg it is clear that CMC provides
better toxicity protection against the drug compound NSC 63479
The dose versus %mean survival curves for the saline and
CMC data above is shown in Fig. 7. The Figure shows the
curves generated from two different vehicles used in the for-
mulation of drug compound NSC 63479. The curves show
that for this particular compound, CMC is clearly more pro-
tective over the common dosage range of 300–10,000mg/kg.
5.2 Classification through pairwise comparison
Using the AUC value over a common dose range for two
different vehicles allowed a pairwise comparison to be made
that distinguished whether one vehicle was more protective
of a particular drug’s toxicity than another. A difference in
the AUC between two vehicles of 30% or greater was set as a
threshold to determine which vehicle was significantly better
at providing toxicity relief over another. Given the challenges
faced with our dataset, which was un-curated and contained
noise that was difficult to measure, we set a large threshold
of 30 % to ensure the differences we observed were related
to vehicle differences rather than noise or experimental vari-
ation. For a particular drug that was used with the vehicles
saline and CMC, if saline resulted in an AUC that was 30 %
or greater than the AUC for CMC this drug was assigned to
the class termed saline > CMC. Likewise if CMC resulted in
an AUC of 30 % or greater, then that particular drug would
be assigned to the class termed CMC > saline. For AUC
differences of less than 30 %, the vehicles were considered
equivalent and not assigned a class.We additionally looked at
larger thresholds to assess how this may influencemodel per-
formance. Thresholds of 40 and 60 % were also considered
in our work (see Sect. 6).
During classification assignment therewere occasions that
resulted in a particular drug being assigned to more than one
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class. This occurred when one set of experiments suggest
that the vehicle saline is more protective than CMC, whilst
for the same drug another set of experiments suggested the
opposite to be true. To ensure drugs were only assigned to
one class we filtered out entirely any drugs that produced
such discrepancies. Removing these drugs reduced the size
of our dataset but this was an import part of the final data
curation before models could be built.
After all our AUC comparisons were made it was evident
that although we began with 39 different vehicle types in our
initial dataset, the largest number of our pairwise compar-
isons were between the vehicles saline and CMC. For this
reason we built a binary classification model based on these
two vehicles, excluding all other vehicles in our dataset for
future work.
We extracted 2221 experimental records that had used
both saline and CMC as a vehicle. These 2221 records corre-
sponded to 1454 unique drug numbers (NSC). This curated
dataset has been included as part of our supplementary data.
Using different thresholds for AUC class assignment meant
the number of drugs varied for each of the models we built
using these thresholds. Of the 1454 unique drug compounds
as the threshold increased from30 to 40 to 60% the number of
compounds in the dataset decreased since more compounds
would naturally be classed as ‘equivalent’ and so removed
from the dataset. See Sect. 6, Table 2, for the number of drugs
remaining in each model we built.
5.3 Chemical structure curation
To build QSAR models, chemical structure information is
required for interpretation of our drugs. We obtained sev-
eral chemical structure files (.sdf) from the DTP website.
These were prepared at various points over the time period
in which the main in vivo dataset was made electronically
available. Whilst some files contained duplicate drug infor-
mation which conflicted with other files, it was considered
that the most recently dated file contained within it the most
accurate information and so structures from this file were
taken in the first instance. Any structures still not identified
were then obtained from the next most recently dated sdf
file and so on until as many drug structures as possible were
identified. Of the 227093 unique drug numbers (NSC) in our
dataset, all but 5510 were identified. Of the 1454 compounds
identified which had data for both saline and CMC, 1405 had
chemical structures suitable for modelling. Records for the
drug structures not available were removed from the dataset.
5.4 Molecular descriptor and fingerprint generation
From the drugs successfully classified, a series of descriptors
were calculated that numerically encode structural features
of the compounds to be processed by our models. A total of
24 molecular property descriptors based on the Indigo tool
kit (Indigo 2010) were calculated using the Molecule Prop-
erties Knime node (version 1.1.4.201308021053). Similarly
MACCS fingerprints were generated using the CDK toolkit
fingerprints Knime node (version 1.5.2.201409032225)
which contains 166 substructure patterns denoted as binary
vectors that indicate the presence or absence of a particular
substructure.
5.5 Descriptor reduction
The diversity captured by these descriptors is vast but to pro-
vide a descriptor pool fromwhich models could be built with
datasets of the sizes shown in Table 2, the descriptors were
objectively screened.
Descriptors which produced a constant value throughout
the dataset were removed from the descriptor pool.
All but one of any two or more descriptors that were
perfectly correlated were also removed. We set a mutual
descriptor correlation coefficient, R2, value of 1, but a value
of 0.9 or above is reported in other studies (Eldred et al. 1999;
Rodgers et al. 2010).
Lastly we correlated the binary class of our compounds
with the remaining descriptor pool. We selected for the high-
est correlating descriptors at a 10:1 ratio of data points to
descriptors. For the DTs, models were built by selecting n/10
descriptors when n data points existed. Whilst for the RFs,
models were built by selecting n/10 descriptors from a pool
of 2n/10 when n data points existed.
For models built using interpolation only at the 60%AUC
threshold (see Table 2), this translates to 7 descriptors (n/10)
given 70 data points (n) for the DTs and 7 descriptors (n/10)
from a pool of 14 (2n/10) given 70 data points (n) for the
RFs.
5.6 Model building
Two machine learning techniques were employed to build
classification predictivemodels; The C.45 decision tree (DT)
and random forest (RF).
C4.5 decision tree (DT) is an algorithm developed by
Quinlan Shafer et al. (1996). Attributes are chosen that most
effectively split the tree into their respective classes. The
attribute exhibiting the highest normalised information gain
is the chosen split criterion. C4.5 then repeats on the smaller
sub-lists. We used no pruning for our DT models and used
the Gini index as a quality measure in their building.
The random forest (RF) (Breiman 2001) is an ensemble
learning method that constructs a multitude of decision trees
and outputs a prediction that is the mode of the classes of
the individual trees. A subset of the training dataset (local
set) is chosen to grow individual trees, with the remaining
samples used to estimate the goodness of fit. Trees are grown
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Table 2 Model output for DT and RF using different threshold values and extrapolation processes
Model Interpolation/
extrapolation
% AUC
threshold
No. of
compounds
Class split
(saline/CMC)
Accuracy (%) Correct
saline (%)
Correct
CMC (%)
Balanced
accuracy (%)
DT Interpolation only 30 148 97/51 60.8 70.1 43.1 56.6
DT Extrapolation high 30 170 105/65 58.2 63.8 49.2 56.5
DT Extrapolation high–low 30 114 67/47 64.9 67.2 61.7 64.4
RF Interpolation only 30 148 97/51 66.2 74.2 51.0 62.6
RF Extrapolation high 30 170 105/65 59.4 66.7 47.7 57.2
RF Extrapolation high–low 30 114 67/47 67.5 74.6 57.4 66.0
DT Interpolation only 40 112 70/42 64.3 77.1 42.9 60.0
DT Extrapolation high 40 136 80/56 68.4 71.2 64.3 67.8
DT Extrapolation high–low 40 89 49/40 73.0 73.5 72.5 73.0
RF Interpolation only 40 112 70/42 71.4 78.6 59.5 69.0
RF Extrapolation high 40 136 80/56 60.3 70.0 46.4 58.2
RF Extrapolation high–low 40 89 49/40 65.2 71.4 57.5 64.5
DT Interpolation only 60 70 45/25 71.4 84.4 48.0 66.2
DT Extrapolation high 60 99 61/38 73.7 82.0 60.5 71.2
DT Extrapolation high–low 60 52 31/21 65.4 67.7 61.9 64.8
RF Interpolation only 60 70 45/25 70.0 82.2 48.0 65.1
RF Extrapolation high 60 99 61/38 72.7 77.0 65.8 71.4
RF Extrapolation high–low 60 52 31/21 80.8 80.6 81.0 80.8
by splitting the local set at each node according to the value
of a random variable sampled independently from a subset
of variables. The number of trees in our RF model was set to
100, with greater values showing no improvement.
Our dataset that contained the binary classes for Saline
> CMC or CMC > Saline was then processed for vehicle
prediction. We employed a 10 fold cross validation training
method. This process utilises 90 % of each class to train on,
whilst predicting the remaining 10 %. This was then iterated
over 10 times to ensure that prediction occurs on all com-
pounds over the 10 iterations.
A flow diagram of the entire methodology is shown in Fig.
8. The inputs are the Input Dataset and the Drug Structures
which are described in Sects. 4 and 5.3. The Data Cura-
tion, Class Curation and Drug Structure Curation steps are
discussed in Sects. 5.1, 5.2 and 5.3 respectively. The soft
computing approaches we used for the Data Extraction and
Model Training steps are described in Sects. 5.1 and 5.6. Our
AUC methodology utilised Extrapolation and Interpolation
techniques which are detailed in Sects. 3.1 and 3.2. Sections
3.3 and 5.4 describe how to Calculate AUC for pairwise clas-
sification and generate molecular properties and fingerprints.
TheDescriptor filter step shows howwe screened for descrip-
tors and is detailed in Sect. 5.5. Finally the Drug-Vehicle
Models we built are described in this section (Sect. 5.6).
The Knime workflow used to build and run our models
has been included in our supplementary data along with our
curated dataset containing saline and CMC relationships and
chemical structures.
6 Results and discussion
Using the experimental methodology discussed above we
ran several prediction models. Given the importance of the
classifier selection threshold (see Sect. 5.1) which in turn
is determined by the interpolation and extrapolation proce-
dures discussed in 3.1 and 3.2 of ourmethodology sectionwe
decided to run ourmodels using 3 different threshold settings
of 30, 40 and 60 %. For each of these 3 different thresholds
we built models on data that were interpolated only with
no extrapolation (Interpolation only), interpolated with high
dose extrapolation (Extrapolation high) and interpolatedwith
extrapolation at the high and low doses (Extrapolation high=-
low). The output of these models is shown in Table 2. From
Table 2 we see that the RF model tends to outperform the
DT on almost all occasions as expected (Diaz-Uriarte and de
Andres 2006; Caruana and Niculescu-Mizil 2006).
We generally see better accuracy values for DT’s and RF’s
as the threshold increases from 30 to 40 to 60 %, possibly
suggesting that the amount of noise in the original dataset is
high and for any signal to be observed the necessary threshold
needs to be high. We did not observe any trends in perfor-
mance as the data defining the AUC range are extrapolated at
one end or both—though the number of compounds included
in the model is consistently greater when extrapolating at the
high end only.
The best predictions we produce come from a RF model
at the 60 % threshold with data extrapolated at the high and
low doses (Extrapolation high–low), which produces a bal-
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Fig. 8 Flowchart of the experimental methodology showing all processes from data curation through to model prediction. The Extrapolation and
Interpolation process are iterative to completion. For simplicity, this loop is not included in the flowchart
anced accuracy of 80.8 %. This model also has individual
prediction accuracies for Saline and CMC of 80.6 and 81.0
% respectively showing that the predictive outcome of the
individual classes is evenly distributed. With the threshold
set so high, i.e. the class discriminator for AUCs set to 60 %
for classes to be assigned, we only produce a dataset of 52
compounds to be modelled.
Although the random forestmodels tend to outperform the
decision trees we gain some insightful scientific information
from the decision trees. Specifically, collecting information
on how the trees are built and what descriptors the branches
split on can provide some interesting scientific interpretation
for our results.
Doing this for the trees built in our models brings up some
interesting findings.Wefind that from the 9 different decision
trees built in our models (each iterated 10 times) there were
five MACCS fingerprints that were used frequently to split
the branches on. These five most common fingerprints were
(position-description); 120-HETEROCYCLIC ATOM >1,
109-ACH2O, 115-CH3ACH2A, 137-HETEROCYCLE and
53-QHAAAQH.
7 Conclusion
In this study we have introduced a methodology that shows
how classifiers can be built on scientific data for model pre-
dictions. We explain the steps of this methodology that is
applicable across many scientific disciplines. We show how
existing scientific data can be repurposed and mined for new
knowledge discovery. An additional innovative feature of our
methodology is the use or our proposed interpolation and
extrapolation to increase the data points used for real world
datasets.
For our experimental work we acquired a large dataset
from the Developmental Therapeutics Program and showed
our methodology to work well and built classifiers that pro-
duce accuracies of 80 %.
This work shows that the effects on toxicity of drugs by
different vehicles can bemodelled, and that well-performing,
interpretable models can be built if sufficient data are avail-
able. To the best of our knowledge this is the first study
building models in this field.
We consider for our future work, extending our current
approaches in dataset preparation to non-linear interpolation
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and extrapolation to deal with survival curve complexity. We
also intend to explore other vehicle relationships that are
contained within our dataset.
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